Evercore analyst Vijay Kumar maintains $Edwards Lifesciences (EW.US)$ with a hold rating, and adjusts the target price from $91 to $70.
According to TipRanks data, the analyst has a success rate of 57.6% and a total average return of 5.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Edwards Lifesciences (EW.US)$'s main analysts recently are as follows:
There is speculation on whether the recent surge in medical technology stocks will sustain as the third-quarter financial reports approach. The sentiment is one of caution, with the third quarter often being the most challenging for the MedTech industry, inviting close examination of the strategies in place for 2025. Discussions regarding forecasts for the upcoming year might influence stock performance in the short term.
In the MedTech sector, the current utilization is sustaining its positive trend into the third quarter and the capital expenditure forecast for the coming year is considered 'healthy'. Regarding life science tools, bioprocess trends are anticipated to show improvement in the latter half of the year. However, there is ongoing discussion concerning the outlook for instruments and the impact of China's stimulus, especially in light of the recent performance of stocks within this sector.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Evercore分析師Vijay Kumar維持$愛德華生命科學 (EW.US)$持有評級，並將目標價從91美元下調至70美元。
根據TipRanks數據顯示，該分析師近一年總勝率為57.6%，總平均回報率為5.6%。
此外，綜合報道，$愛德華生命科學 (EW.US)$近期主要分析師觀點如下：
有人猜測，隨着第三季度財務報告的臨近，近期醫療科技股的飆升是否會持續下去。這種情緒是謹慎的，第三季度通常是醫療技術行業最具挑戰性的季度，因此需要仔細研究2025年制定的戰略。關於來年預測的討論可能會在短期內影響股票表現。
在醫療科技領域，目前的利用率在第三季度一直保持積極的趨勢，來年的資本支出預測被認爲是 「健康的」。在生命科學工具方面，生物工藝趨勢預計將在下半年顯示出改善。但是，關於工具前景和中國刺激措施影響的討論仍在繼續，特別是考慮到該行業股票的近期表現。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
